Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (1-10 of 217) with videos related to

Pageof 22
Sort By:
Nature Clinical Practice. Oncology|March 8, 2006
Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials?Alexandra Leary, Ian Smith
Bulletin Du Cancer|October 22, 2017
[Abnormalities of DNA repair and gynecological cancers]Aurélie Auguste, Alexandra Leary
Frontiers in Oncology|December 30, 2021
Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1Laure Chardin, Alexandra Leary
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2025
Controversies in the management of mucinous ovarian tumorsFélix Blanc-Durand, Alexandra Leary
The New England Journal of Medicine|March 28, 2019
Mucinous Ovarian CarcinomaPhilippe Morice, Sebastien Gouy, Alexandra Leary
Current Opinion in Oncology|July 26, 2016
DNA damage response as a therapeutic target in gynecological cancersAlexandra Leary, Aurelie Auguste, Soizick Mesnage
The New England Journal of Medicine|July 4, 2019
Mucinous Ovarian Carcinoma. ReplyPhilippe Morice, Alexandra Leary, Sebastien Gouy
Gynecologic Oncology|June 16, 2012
Are the outcomes of neoadjuvant chemotherapy for stage IB2 cervical cancer similar in pregnant and nonpregnant patient?Philippe Morice, Catherine Uzan, Alexandra Leary
Chinese Journal of Cancer|January 6, 2015
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesBianca Cheaib, Aurélie Auguste, Alexandra Leary
Lancet (London, England)|December 11, 2023
The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncologyAlexandra Leary, Benjamin Besse, Fabrice André
Pageof 22

Showing results (1-10 of 217) with videos related to

Sort By:
Pageof 22
Nature Clinical Practice. Oncology|March 8, 2006
Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials?Alexandra Leary, Ian Smith
Bulletin Du Cancer|October 22, 2017
[Abnormalities of DNA repair and gynecological cancers]Aurélie Auguste, Alexandra Leary
Frontiers in Oncology|December 30, 2021
Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1Laure Chardin, Alexandra Leary
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2025
Controversies in the management of mucinous ovarian tumorsFélix Blanc-Durand, Alexandra Leary
The New England Journal of Medicine|March 28, 2019
Mucinous Ovarian CarcinomaPhilippe Morice, Sebastien Gouy, Alexandra Leary
Current Opinion in Oncology|July 26, 2016
DNA damage response as a therapeutic target in gynecological cancersAlexandra Leary, Aurelie Auguste, Soizick Mesnage
The New England Journal of Medicine|July 4, 2019
Mucinous Ovarian Carcinoma. ReplyPhilippe Morice, Alexandra Leary, Sebastien Gouy
Gynecologic Oncology|June 16, 2012
Are the outcomes of neoadjuvant chemotherapy for stage IB2 cervical cancer similar in pregnant and nonpregnant patient?Philippe Morice, Catherine Uzan, Alexandra Leary
Chinese Journal of Cancer|January 6, 2015
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesBianca Cheaib, Aurélie Auguste, Alexandra Leary
Lancet (London, England)|December 11, 2023
The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncologyAlexandra Leary, Benjamin Besse, Fabrice André
Pageof 22